Phase 2 Ovarian Cancer Trial, Recruiting NCT05704621 Sponsor: Korea University Guro Hospital Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 2 Ovarian Cancer Trial, Recruiting

NCT05704621
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has come back for the first time
  • Your cancer is the type that grows from the lining of the organs (called epithelial), at any original stage
  • Your cancer came back at least 6 months after you finished your last platinum-based chemotherapy treatment
  • Your cancer got worse while you were taking a PARP inhibitor maintenance treatment
  • You are a woman aged 18 or older
  • A specialist surgeon believes it is likely that all visible cancer can be completely removed by surgery
  • Your scan results (using a scoring system called AGO-score or iMODEL+PET/CT) suggest surgery could fully remove the cancer, OR your surgeon and a specialist radiologist both agree complete removal is likely even if the score is not positive (confirm with trial site)
  • You are willing and able to sign a consent form agreeing to take part and to allow your data to be used

Who may not be able to join:

  • Your cancer is not the epithelial type, or has been classified as a "borderline" tumour
  • You do not currently have a recurrence and are being considered for a check-up or clean-up surgery after chemotherapy
  • You have had more than one course of chemotherapy in the past
  • Your cancer has come back more than once before (second, third, or later recurrence)
  • You have or have had another cancer that was treated with abdominal surgery, or another cancer whose treatment could interfere with treating your ovarian cancer or significantly affect your outlook
  • Your cancer is considered "platinum-refractory," meaning it progressed during platinum chemotherapy or came back within 6 months of finishing your first platinum-based treatment
  • Only palliative (comfort-focused, non-curative) surgery is being planned for you
  • Your scans show cancer that cannot be fully removed by surgery
  • You have another health condition that would make surgery or chemotherapy unsafe for you
  • Your medical history suggests you would face very high risks during or after surgery
  • You are currently taking a medication that could cause serious problems during surgery, for example blood thinners or certain cancer drugs that increase bleeding risk (confirm with trial site)
  • There is no stored tumour tissue available from your previous diagnosis that can be tested

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Hyun-Woong Cho, MD. PhD., Korea University Guro Hospital

Phone: 82-2-2626-3228

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Korea University Guro Hospital
Registry
ClinicalTrials.gov
Start date
1 December 2023
Est. completion
28 December 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

progression-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov